therapy that is optimal for disease control in patients with HR-LPCa. In this study, we compared the long-term oncological outcomes of RP and intensity-modulated radiation therapy (IMRT) for HR-LPCa at our institution using a propensity score-matched analysis.
INTRODUCTION AND OBJECTIVES:
We evaluated the efficacy and safety of prostate-directed radiotherapy with or without metastasis-directed radiotherapy in de novo oligometastatic patients who underwent combination of high-dose-rate prostate brachytherapy, external beam radiotherapy, and androgen deprivation therapy.
METHODS: Forty patients with bone metastasis and node positive prostate cancer were retrospectively analyzed. Of these, 22 (55%), 3 (7%), and 15 (38%) patients had N1M0, M1a, and M1b, respectively. Eighteen patients (45%) received metastasis-directed radiotherapy to all metastatic sites. All patients initially underwent ! 6 months of androgen deprivation therapy. Oligometastatic disease was defined as presence of five or fewer metastatic lesions. Median prostate-specific antigen (PSA) at diagnosis and follow-up period was 19.35 ng/ml and 62.5 months, respectively. RESULTS: Of the 40 patients, the 5-year castration-resistant prostate cancer (CRPC)-free survival rate and cancer-specific survival was 64.4% and 87.9%, respectively. Pre-treatment predictive value including PSA at diagnosis ! 20 ng/ml (HR 2.722; 95% CI: 1.003-7.392), positive biopsy core rate ! 51% (HR 4.677; 95% CI: 1.693-12.92), and Gleason grade group 5 (HR 2.993; 95% CI: 1.246-12.34) were significantly associated with worse outcomes for CRPC-free survival. Patients with metastasis-directed radiotherapy had significantly higher probability of achieving a PSA level of < 0.02 ng/ ml than those without the therapy (88.8% vs. 54.5%, p [ 0.0354) and consequently had a better CRPC-free survival than those without the therapy (HR 0.319; 95% CI: 0.116-0.877) (Figure 1 METHODS: We evaluated 2,277 men who underwent PPB AE EBRT for localized prostate cancer. Primary outcomes were patientreported incontinence (PRI) at last follow up visit, type of incontinence reported, and patient-reported pad use (PRP) at last follow up visit. The association of patient, disease, and treatment characteristics with PRI and PRP was assessed. Univariate analysis was performed using chi-squared, fisher's exact, student's t-test, and ANOVA. Multivariate analysis was performed using binomial and multinomial logistic regression.
RESULTS: Median follow up was 100 months. In total, 82 patients (3.6%) reported unresolved incontinence at last follow up, while only 17 reported using at least one pad. For patients reporting incontinence, 59 reported urge incontinence, 15 reported stress incontinence , and 8 reported mixed incontinence. Of the 17 patients using pads, 12 reported urge incontinence and 5 reported mixed incontinence, while none reported stress incontinence. In univariate analysis, the factors associated with increased PRI were post-treatment TURP (p[0. CONCLUSIONS: Overall rates of incontinence following PPB are low, whether measuring PRI or PRP. However, there is discordance between these metrics. Pre-and post-treatment TURP remain the strongest factors associated with post-procedural incontinence, though history of diabetes and EBRT are associated with increased urge incontinence, and higher NCCN risk is associated with increased stress incontinence.
Source of Funding: None

MP72-15 DETERMINING THE MARGINAL BENEFIT OF ADJUVANT HORMONAL THERAPY IN INTERMEDIATE RISK PROSTATE CANCER PATIENTS WITH INSUFFICIENT DOSE DELIVERED BY PERMANENT PROSTATE BRACHYTHERAPY
Jared Winoker*, Rollin Say, Conner Brown, Richard Stock, Nelson Stone, New York, NY INTRODUCTION AND OBJECTIVES: Owing to toxicity concerns with combination therapy, there has been a contemporary trend toward use of monotherapeutic brachytherapy (BT) for the treatment of localized prostate cancer (PC). Standard of care calls for a dose prescription sufficient to attain a D90 of !140 Gy with iodine, or a biological equivalent dose (BED) of 154 Gy2. For patients with insufficient dose delivered as determined on post-implant dosimetry, practitioners may initiate adjuvant external beam radiation (EBRT) or hormonal therapy (HT) to improve oncological outcomes, particularly in intermediate or high risk disease patients. We sought to quantify the marginal benefit gained by the addition of HT as a function of BED.
METHODS: Among 2277 men who underwent BT AE EBRT from 1990 to 2015, 688 (30%) men with intermediate risk disease were identified. We evaluated the influence of receiving HT at various maximum BED cut-points with respect to freedom from biochemical failure (FFbF), as defined by Phoenix criteria (nadir PSA þ 2 ng/ml). Ten-year FFbF was estimated by Kaplan Meier method. A cut-point of BED <150 with HT was set as the reference standard against which we tested other BED levels in the absence of HT. Chi-square test was used to evaluate difference in 10-year FFbF between the various BED levels.
RESULTS: Median follow up was 8.3 years (range, 2.8-21.8). Median age was 67 years (range, 41-84) and median PSA was 8.4 ng/ ml (range, 1-20). The 10-year FFbF for men receiving BED <150 with HT was 81.6%. Compared to this reference group, FFbF was worse for men with BED <150 (p[.002) and <160 (p[.021) without HT. However, this statistical significance was lost at BED <170 (p[.319) and for higher cut-points as there was no difference to the baseline group (BED <150 with HT) in terms of FFbF.
CONCLUSIONS: In the case of a post-dosimetry BED <150, intermediate risk patients gain an oncologic benefit from the addition of 6 months of HT, equivalent to receiving a BED of at least 170 Gy2 without HT. Alternatively, this marginal benefit of 20 BED from the addition of adjuvant HT also corresponds to receiving 2 weeks of EBRT at 1.8 Gy/ fraction.
Source of Funding: none
MP72-16 COMPARISON BETWEEN 3 TECHNIQUES FOR THE TREATMENT OF RADIATION-INDUCED HEMORRHAGIC CYSTITIS: GREENLIGHT XPS LASER, HOLMIUM LASER, AND MONOPOLAR ELECTROCOAGULATION
Isma€ el Chelghaf*, Quentin Alimi, Karim Bensalah, Peyronnet Benoit, Nantes, France INTRODUCTION AND OBJECTIVES: Radiation-induced hemorrhagic cystitis is the most frequent sequelae of pelvic radiotherapy. Its induce frequent hospitalizations, surgical interventions, and blood transfusions. Multiple treatments have been tried, but the management of this damages is difficult and ill-defined.
The aim of the study was to compare efficacy and safety of coagulation for telangiectasias and hemorrhagic cystitis, with Greenlight XPS laser, Holmium laser, and monopolar electrocoagulation.
METHODS Median follow-up was 13, 38, and 58 months (p<0.0001), and hematuria recurrence rate was higher in Holmium laser group (39% vs 50% vs 80% ; p[0.02). However survived without treatment (surgery or hyperbaric oxygen) were comparable between the 3 groups (p[0.56).
CONCLUSIONS: For patient suffering from hematuria, caused by radiation-induced cystitis, efficacy of coagulation by GreenLight XPS laser seemed higher than monopolar or Holmium laser. These results must be confirmed by long-term data and more cases.
Source of Funding: none
MP72-17
